SCHEMBL6186844

SCHEMBL6186844

C[C@H](NC(=O)Cn1c(CN(C(=O)OCc2ccccc2)c2ccc(OC3CCN(C(=O)OC(C)(C)C)CC3)cc2)nc2cc(C#N)ccc21)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
F10 P00742 15/20 0.56
GPR119 Q8TDV5 1/20 0.41
YAP1 P46937 3/20 0.38
P2RX7 Q99572 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6186841 1.00 F10 (0.56) F10GPR119YAP1P2RX7
SCHEMBL6187724 0.91 GPR119 (0.46) F10GPR119
SCHEMBL6190762 0.88 F10 (0.64) F10GPR119
SCHEMBL6190756 0.88 F10 (0.64) F10GPR119
SCHEMBL6186837 0.84 GPR119 (0.41) F10GPR119YAP1P2RX7
SCHEMBL6186994 0.80 F10 (0.51) F10GPR119
SCHEMBL6192780 0.79 F10 (0.78) F10
SCHEMBL6186585 0.78 F10 (0.53) F10GPR119
SCHEMBL6190950 0.76 GPR119 (0.56) F10GPR119
SCHEMBL6187947 0.75 F10 (0.62) F10GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1070714-A9 AMIDINE COMPOUNDS JAPAN TOBACCO INC. (JP) 2005-10-19 EP disclosed
US-20040006099-A1 Amidine compounds JAPAN TOBACCO INC. 2004-01-08 US disclosed
US-6562828-B1 Novel amidine compound having a blood coagulation factor Xa inhibitory activity JAPAN TOBACCO INC. (JP) 2003-05-13 US disclosed
EP-1070714-A1 AMIDINE COMPOUNDS JAPAN TOBACCO INC. (JP) 2001-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006099-A1 Amidine compounds F2, SERPINC1, F12 F10 16/4885GPR119 2900/4885YAP1 4600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.